The ousted director of a key U.S. agency charged with developing drugs to fight the COVID-19 pandemic said Wednesday he was dismissed because he called for careful vetting of a treatment frequently touted by President Donald Trump.
Rick Bright said in a statement that he was replaced as director of the Biomedical Advanced Research and Development Authority, or BARDA, and reassigned to a new role because he resisted efforts to push hydroxychloroquine and the related chloroquine as cures for COVID-19, the respiratory illness caused by the new coronavirus.
"While I am prepared to look at all options and to think 'outside the box' for effective treatments, I rightly resisted efforts to provide an unproven drug on demand to the American public," Bright said in the statement, reported by multiple U.S. media outlets Wednesday.
With your current subscription plan you can comment on stories. However, before writing your first comment, please create a display name in the Profile section of your subscriber account page.